Melanotan-2 research covers MC1R and MC4R agonism, skin pigmentation in animal models, and neuroprotective melanocortin signalling in preclinical studies.
Orforglipron GLP-1 research: non-peptide small molecule, oral bioavailability, ATTAIN phase 3 data, and mechanistic comparison to semaglutide and tirzepatide.
NAD+ research in preclinical models reveals sirtuin activation, PARP competition, and mitochondrial effects. Review the evidence on NAD+ and longevity.
Preclinical research on Pinealon (EDR tripeptide): epigenetic mechanisms, neuroprotective effects in animal models, and cognitive aging from the Khavinson lab.
Explore preclinical and clinical research on Tesamorelin, a 44-amino acid GHRH analog studied for visceral adiposity, GH pulse dynamics, and metabolic markers.
Preclinical research on CJC-1295, a GHRH analog studied for GH pulse amplification, IGF-1 axis modulation, and body composition effects in animal models.
Explore preclinical research on GHK-Cu copper peptide, covering collagen synthesis, wound healing models, anti-fibrotic signaling, and gene expression data.
Preclinical research on Selank explores GABA-A modulation, anxiolytic effects in rodent stress models, and BDNF upregulation without dependence or tolerance.
Explore preclinical research on MOTS-c peptide, the mitochondrial-derived peptide encoded in 12S rRNA linked to glucose homeostasis and AMPK activation.
Oral BPC-157 dosing protocols in rodent studies: dose ranges in µg/kg, gavage vs drinking water, administration schedules, and endpoint timing reviewed.
RESEARCH NOTES
107 papers across 7 compound categories.